Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 20.58%1.46T | 15.78%5.37T | 24.25%1.53T | 8.04%1.29T | 16.73%1.35T | 13.69%1.21T | 30.08%4.64T | 23.62%1.23T | 32.70%1.2T | 39.35%1.15T |
Cost of revenue | 16.52%1.06T | 13.41%3.96T | 21.63%1.12T | 4.51%941.92B | 14.37%987.83B | 12.91%908.5B | 28.75%3.49T | 20.61%922.12B | 31.46%901.25B | 36.52%863.7B |
Gross profit | 32.85%399.08B | 23.00%1.41T | 32.12%405.2B | 18.84%349.48B | 23.73%359.36B | 16.11%300.4B | 34.27%1.15T | 33.64%306.7B | 36.68%294.08B | 48.49%290.44B |
Operating expense | 20.40%241.53B | 18.70%948.87B | 28.31%286.29B | 25.87%240.97B | 10.17%221.03B | 8.90%200.59B | 20.21%799.38B | 20.81%223.13B | 14.22%191.44B | 32.89%200.61B |
Selling and administrative expenses | --244.23B | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
-General and administrative expense | --244.23B | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Other operating expenses | --3.11B | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Total other operating income | --5.81B | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Operating profit | 57.87%157.56B | 32.81%465.56B | 42.29%118.91B | 5.73%108.52B | 53.99%138.33B | 33.94%99.8B | 83.09%350.55B | 86.54%83.57B | 115.86%102.64B | 101.21%89.83B |
Net non-operating interest income (expenses) | 700.14%27.93B | -46.90%16.55B | -42.11%4.02B | -396.35%-31.05B | 727.94%40.09B | -60.81%3.49B | -48.84%31.17B | 168.69%6.94B | 375.79%10.48B | 48.16%4.84B |
Non-operating interest income | 523.05%31.62B | -29.81%26.61B | -7.81%8.72B | -367.26%-33.7B | 704.74%46.51B | -49.54%5.08B | -43.31%37.91B | 76.75%9.46B | 265.27%12.61B | 30.48%5.78B |
Non-operating interest expense | 133.12%3.7B | 49.19%10.06B | 86.71%4.71B | -224.30%-2.65B | 584.85%6.42B | 37.59%1.59B | 13.22%6.74B | -9.03%2.52B | 70.56%2.13B | -19.29%937M |
Net investment income | 69.19%-3.76B | 158.46%4.28B | -88.28%446M | -304.35%-12.22B | -284.17%-7.33B | -388.27%-8.82B | 112.60%132M | |||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 3,497.50%1.44B | 3,886.11%1.44B | 0 | -93.42%40M | -94.04%36M | 4M | 0 | |||
Income from associates and other participating interests | 22.93%4.05B | 5.36%12.23B | -0.13%2.97B | 16.11%2.86B | -16.08%3.11B | 33.44%3.29B | 25.56%11.61B | 11.83%2.97B | 14.49%2.47B | 65.00%3.71B |
Special income (charges) | 62.07%-687M | 52.94%-1.13B | 227.78%354M | -116.84%-1.81B | -225.24%-2.4B | 96.39%381M | 101.04%97M | |||
Less:Other special charges | ---- | 26.11%-549M | 31.21%-108M | ---- | ---- | -227.78%-354M | 95.97%-743M | -82.56%-157M | -96.39%-381M | 39.75%-97M |
Less:Write off | ---- | -51.61%1.24B | ---- | ---- | ---- | ---- | -66.77%2.55B | ---- | ---- | ---- |
Other non-operating income (expenses) | -220.98%-2.05B | -25.22%-2.39B | 828.85%966M | 136.22%1.7B | -138.01%-1.91B | -176.56%-503M | 134.24%4.01B | |||
Income before tax | 74.92%189.53B | 28.41%489.28B | 56.44%128.1B | -31.48%73.07B | 75.18%179.76B | 20.52%108.35B | 38.92%381.04B | 33.00%81.88B | 91.04%106.64B | 265.76%102.61B |
Income tax | 53.13%47.56B | 35.87%145.05B | 25.67%39.34B | -6.19%18.68B | 68.99%55.98B | 38.53%31.06B | 43.26%106.76B | 5.99%31.31B | 39.98%19.91B | 227.93%33.12B |
Net income | 83.68%141.97B | 25.50%344.23B | 75.48%88.76B | -37.29%54.39B | 78.14%123.79B | 14.54%77.3B | 37.31%274.28B | 57.92%50.58B | 108.50%86.73B | 287.07%69.49B |
Net income continuous operations | 83.68%141.97B | 25.50%344.23B | 75.48%88.75B | -37.29%54.39B | 78.14%123.79B | 14.54%77.3B | 37.31%274.28B | 57.91%50.58B | 108.51%86.73B | 287.04%69.49B |
Noncontrolling interests | 170.98%27.74B | 43.90%76.51B | 48.77%19.15B | -59.93%7.39B | 213.73%39.74B | 11.28%10.24B | 34.91%53.17B | 72.30%12.87B | 191.05%18.44B | 481.06%12.67B |
Net income attributable to the company | 70.35%114.23B | 21.08%267.72B | 84.60%69.61B | -31.17%47B | 47.91%84.05B | 15.06%67.06B | 37.89%221.11B | 53.54%37.71B | 93.68%68.29B | 260.24%56.82B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 70.35%114.23B | 21.08%267.72B | 84.60%69.61B | -31.17%47B | 47.91%84.05B | 15.06%67.06B | 37.89%221.11B | 53.54%37.71B | 93.68%68.29B | 260.24%56.82B |
Gross dividend payment | ||||||||||
Basic earnings per share | 71.57%59.21 | 21.62%138.4 | 86.04%36.0725 | -30.60%24.3975 | 48.43%43.42 | 15.01%34.51 | 37.86%113.8 | 53.37%19.39 | 93.65%35.1525 | 260.25%29.2525 |
Diluted earnings per share | 71.57%59.21 | 21.61%138.39 | 86.00%36.065 | -30.48%24.395 | 48.43%43.42 | 15.02%34.51 | 37.86%113.8 | 53.37%19.39 | 93.31%35.09 | 260.25%29.2525 |
Dividend per share | 0 | 22.00%30.5 | 34.00%16.75 | 0 | 10.00%13.75 | 0 | 9.89%25 | 8.70%12.5 | 0 | 11.11%12.5 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |